Lilly Reports Disappointing Data on Alzheimer’s Candidate

This post was originally published on this site

Eli Lilly and Company LLY announced failure to meet endpoint in a phase II/III study on pipeline candidate, solanezumab, in patients with a rare inherited form of Alzheimer’s disease (“AD”). The phase II/III study, DIAN-TU, is sponsored by the Washington …

Click here to read full article